Top

Published in:

Open Access 01-12-2024 | Research

Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals

Authors: Reem El-Shenawy, Rehab I. Moustafa, Naiera M. Helmy, Yasmine S. El-Abd, Ashraf A. Tabll, Yasser K. Elesnawy, Heba Shawky

Published in: Virology Journal | Issue 1/2024

Abstract

Background

Although direct-acting antivirals (DAAs) have revolutionized the management of chronic HCV, the debatable association with hepatocellular carcinoma (HCC) occurrence/recurrence has raised major concerns about their long-term use, especially in cirrhotic cases. The role of epithelial tight junction proteins (TJPs) in hepatocarcinogenesis has been highlighted; however, the association of their expression in peripheral blood mononuclear cells (PBMCs) with HCC has rarely been reported. This study aimed to explore the role of peripheral claudin (Cldn)1 in liver pathogenesis and its crosstalk with soluble immune mediators in HCC prognosis.

Methods

The study population included six independent subgroups: healthy controls, cirrhotic/non-cirrhotic treatment-naïve HCV patients, DAA-SVR patients, and anticancer treatment-naïve de novo HCC patients. The laboratory tests included serum levels of alpha-fetoprotein (AFP), albumin, liver transaminases, total bilirubin, and CBC profiling. The serum levels of soluble cluster of differentiation (sCD)163, IL-10, and IL-12 were estimated by corresponding ELISA kits, whereas the levels of Cldn1 and transforming growth factor (TGF)-β in PBMCs were quantified using quantitative PCR (qPCR).

Results

Serum sCD163, IL-10, and IL-12 levels were significantly higher in the HCC patient group than in the control and non-malignant patient groups (P < 0.0001). No significant difference was detected in the serum levels of the three markers between cirrhotic and non-cirrhotic patients, whereas their levels were significantly different between cirrhotic and non-cirrhotic patients (P < 0.0001). Similarly, the transcriptional levels of peripheral Cldn1 and TGF-β were significantly higher in patients with HCC and non-malignant cirrhosis than in patients without cirrhosis (P = 0.0185–<0.0001 and 0.0089–<0.0001, respectively). Logistic regression analysis revealed a significant association between all the abovementioned markers and HCC (P = 0.0303 to < 0.0001), which was further confirmed by the results of receiver operating characteristic (ROC) analysis, which revealed an area under the curve (AUC) value ranging from 0.883 to 0.996. The calculated cutoff values demonstrated remarkable prognostic capacity, with ranges of 88–99.41% and 82.14–97.92% and positive/negative predictive values ranging from 84.62 to 98.3% and 92–98%, respectively.

Conclusion

The proposed HCC predictors are novel non-invasive HCC biomarkers that maintain their predictive power under different pathological conditions and circumvent the drawbacks of conventional prognostic markers in patients with mild cirrhosis and/or normal AFP, albumin, and/or platelet counts.

Available only for authorised users

Chon YE, Park SY, Hong HP, Son D, Lee J, Yoon E, Kim SS, Ahn SB, Jeong SW, Jun DW. Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly. Clin Mol Hepatol. 2023;29(1):120–34. https://doi.org/10.3350/cmh.2021.0395CrossRefPubMed

Omar MA, Omran MM, Farid K, Tabll AA, Shahein YE, Emran TM, Petrovic A, Lucic NR, Smolic R, Kovac T, Smolic M. Biomarkers for Hepatocellular Carcinoma: from origin to clinical diagnosis. Biomedicines. 2023;11(7):1852. https://doi.org/10.3390/biomedicines11071852CrossRefPubMedPubMedCentral

Suhail M, Sohrab SS, Kamal MA, Azhar EI. Role of hepatitis C virus in hepatocellular carcinoma and neurological disorders: an overview. Front Oncol. 2022;12:913231. https://doi.org/10.3389/fonc.2022.CrossRefPubMedPubMedCentral

Ahn YH, Lee H, Han JE, Cho HJ, Cheong JY, Park B, Kim SS. Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment. J Liver Cancer. 2022;22(2):125–35. https://doi.org/10.17998/jlc.2022.05.24CrossRefPubMedPubMedCentral

Tampaki M, Savvanis S, Koskinas J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. Ann Gastroenterol. 2018;31(6):670–9. https://doi.org/10.20524/aog.2018.0306CrossRefPubMedPubMedCentral

Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk factors contributing to the occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus patients treated with Direct-Acting Antivirals. Biomedicines. 2020;8(6):175. https://doi.org/10.3390/biomedicines8060175CrossRefPubMedPubMedCentral

Sweed D, Sweed E, Moaz I, Mosbeh A, Fayed Y, Elhamed SMA, Sweed E, Macshut M, Abdelsattar S, Kilany S, Saied SA, Badr R, Abdallah MS, Ehsan N. The clinicopathological and prognostic factors of hepatocellular carcinoma: a 10-year tertiary center experience in Egypt. World J Surg Oncol. 2022;20(1):298. https://doi.org/10.1186/s12957-022-02764-2CrossRefPubMedPubMedCentral

Chow VYS, Cheung WI. Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong. BMC Gastroenterol. 2024;24(1):49. https://doi.org/10.1186/s12876-023-03099-2CrossRefPubMedPubMedCentral

Moschouri E, Salemme G, Baserga A, Cerny A, Deibel A, Müllhaupt B, Meier MA, Bernsmeier C, Ongaro M, Negro F, Grosjean M, Clerc O, Künzler-Heule P, Semela D, Hobi G, Stickel F, Mathieu A, Mdawar-Bailly E, Faouzi M, Moradpour D, Fraga M. Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis. Swiss Med Wkly. 2024;154(6):3698. https://doi.org/10.57187/s.3698CrossRefPubMed

10.

Rinaldi L, Nevola R, Franci G, Perrella A, Corvino G, Marrone A, Berretta M, Morone MV, Galdiero M, Giordano M, Adinolfi LE, Sasso FC. Risk of hepatocellular carcinoma after HCV clearance by direct-acting antivirals treatment predictive factors and role of epigenetics. Cancers (Basel). 2020;12(6):1351.CrossRefPubMed

11.

Witte M, Oltmanns C, Tauwaldt J, Schmaus H, Mischke J, Grabert G, Bretthauer M, Deterding K, Maasoumy B, Wedemeyer H, Kacprowski T. The impact of cirrhosis on the inflammatory milieu before and long-term after hepatitis C virus elimination by direct-acting antiviral therapy. medRxiv. 2023:2023-10. https://doi.org/10.1101/2023.10.31.23297828

12.

Alqahtani SA, Sulkowski MS. Chronic hepatitis C: advances in Therapy and the remaining challenges. Med Clin North Am. 2023;107(3):423–33. https://doi.org/10.1016/j.mcna.2023.01.001CrossRefPubMed

13.

Das M. Egypt launches 100 healthy days health-care campaign. Lancet Oncol. 2023;24(8):845. https://doi.org/10.1016/s1470-2045(23)00338-8CrossRefPubMed

14.

Gu J, Zhang X, Cui R, Zhang J, Wang Z, Jia Y, Miao R, Dong Y, Ma X, Fan H, Wang H, Ren L, Li Y, Niu W, Zhang J, Qu K, Liu C. Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2019;31(7):836–44. https://doi.org/10.1097/meg.0000000000001346CrossRefPubMed

15.

Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–29. https://doi.org/10.1111/liv.14223CrossRefPubMed

16.

Wang T, Zhang KH. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front Oncol. 2020;10:1316. https://doi.org/10.3389/fonc.2020.01316CrossRefPubMedPubMedCentral

17.

Manuc D, Preda CM, Sandra I, Baicus C, Cerban R, Constantinescu I, Olteanu AO, Ciora CA, Manuc T, Chiriac DE, Chifulescu AE, Diculescu M, Tieranu C, Negreanu L, Oprea-Calin G, Manuc M. Signification of serum alpha-fetoprotein levels in cases of compensated cirrhosis and hepatitis C virus without hepatocellular carcinoma. J Med Life. 2020;13(1):68–74. https://doi.org/10.25122/jml-2019-0076.CrossRefPubMedPubMedCentral

18.

Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DT. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022;28(2):216–29. https://doi.org/10.3748/wjg.v28.i2.216.CrossRefPubMedPubMedCentral

19.

Mirshahi F, Aqbi HF, Isbell M, Manjili SH, Guo C, Saneshaw M, Bandyopadhyay D, Dozmorov M, Khosla A, Wack K, Carrasco-Zevallos OM, Idowu MO, Wang XY, Sanyal AJ, Manjili MH. Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. Cell Rep. 2022;38(9):110454. https://doi.org/10.1016/j.celrep.2022.110454CrossRefPubMedPubMedCentral

20.

Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The role of cytokines in the different stages of hepatocellular carcinoma. Cancers (Basel). 2021;13(19):4876. https://doi.org/10.3390/cancers13194876CrossRefPubMed

21.

Mirlekar B. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: its implications in cancer immunotherapy. SAGE Open Med. 2022;10:20503121211069012. https://doi.org/10.1177/20503121211069012CrossRefPubMedPubMedCentral

22.

Amoras EDSG, Monteiro Gomes ST, Freitas Queiroz MA, de Araújo MSM, de Araújo MTF, da Silva Conde SRS, Ishak R, Vallinoto ACR. Intrahepatic interleukin 10 expression modulates fibrinogenesis during chronic HCV infection. PLoS ONE. 2020;15(10):e0241199. https://doi.org/10.1371/journal.pone.0241199CrossRefPubMedPubMedCentral

23.

Saleh A, Saed AM, Mansour M. Association of IL-10 and TNF-α polymorphisms with risk and aggressiveness of hepatocellular carcinoma in patients with HCV-related cirrhosis. Egypt Liver J. 2020;10:1–8. https://doi.org/10.1186/s43066-020-00052-wCrossRef

24.

Sakr MA, Mohamed KA, Hussein AM, Fouad MH, Allam AS, Safwat E. Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy. Egypt Liver J. 2021;11(22):1–10. https://doi.org/10.1186/s43066-021-00090-yCrossRef

25.

Wen Y, Zhu Y, Zhang C, Yang X, Gao Y, Li M, Yang H, Liu T, Tang H. Chronic inflammation, cancer development and immunotherapy. Front Pharmacol. 2022;13:1040163. https://doi.org/10.3389/f phar.2022.1040163.CrossRefPubMedPubMedCentral

26.

Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Clinical and prognostic biomarker value of blood-circulating inflammatory cytokines in hepatocellular carcinoma. Oncology. 2023;101(11):730–7. https://doi.org/10.1159/000531870CrossRefPubMed

27.

Zeisel MB, Dhawan P, Baumert TF. Tight junction proteins in gastrointestinal and liver disease. Gut. 2019;68(3):547–61. https://doi.org/10.1136/gutjnl-2018-316906CrossRefPubMed

28.

Saviano A, Roehlen N, Baumert TF. Tight junction proteins as therapeutic targets to treat liver fibrosis and hepatocellular carcinoma. Semin Liver Dis. 2024. https://doi.org/10.1055/s-0044-1785646CrossRefPubMed

29.

Roehlen N, Muller M, Nehme Z, Crouchet E, Jühling F, Del Zompo F, et al. Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment. J Hepatol. 2023;78(2):343–55. https://doi.org/10.1016/j.jhep.2022.10.011CrossRefPubMed

30.

Griffiths JI, Wallet P, Pflieger LT, Stenehjem D, Liu X, Cosgrove PA, Leggett NA, McQuerry JA, Shrestha G, Rossetti M, Sunga G, Moos PJ, Adler FR, Chang JT, Sharma S, Bild AH. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc Natl Acad Sci U S A. 2020;117(27):16072–82. https://doi.org/10.1073/pnas.1918937117CrossRefPubMedPubMedCentral

31.

Hu R, Zhang W, Han Z, Ma M, Huang Q, Lv M, Ma W, Sun X, Feng W, Li J, Zhong X, Sun J, Yao W, Zhou X. Identification of immune-related target and prognostic biomarkers in PBMC of hepatocellular carcinoma. BMC Gastroenterol. 2023;23(1):234. https://doi.org/10.1186/s12876-023-02843-yCrossRefPubMedPubMedCentral

32.

Ragazzo TG, Paranagua-Vezozzo D, Lima FR, de Campos Mazo DF, Pessoa MG, Oliveira CP, Alves VAF, Carrilho FJ. Accuracy of transient elastography-FibroScan^®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. Clin (Sao Paulo). 2017;72(9):516–25. https://doi.org/10.60 61/clinics/2017(09)01.CrossRef

33.

Naga IS, Kamel AA, Ooda SA, Elbab HM, El-Sharkawy RM. Effect of directly acting anti-viral agents on immunological imprints in chronic HCV-4a patients: interleukin-10 and vascular endothelial growth factor genes expression level. Egypt Liver J. 2021;11(1):35. https://doi.org/10.1186/s43066-021-00108-5CrossRef

34.

Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O’Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–8. https://doi.org/10.1200/jc o.2014.57.9151.CrossRefPubMed

35.

Zhao S, Wang M, Yang Z, Tan K, Zheng D, Du X, Liu L. Comparison between child Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. Ann Transl Med. 2020;8(8):539. https://doi.org/10.21037/atm.2020.02.85.CrossRefPubMedPubMedCentral

36.

Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93. https://doi.org/10.1016/j.jhep.2021.11.018CrossRefPubMed

37.

Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M, Vendemiale G, Serviddio G. DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-hcv treatment. PLoS ONE. 2016;11(12):e0167934. https://doi.org/10.1371/journal.pone.0167934CrossRefPubMedPubMedCentral

38.

Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol. 2022;14(6):1053–73. https://doi.org/10.4254/wjh.v14.i6.1053.CrossRefPubMedPubMedCentral

39.

Quaranta MG, Cavalletto L, Russo FP, Calvaruso V, Ferrigno L, Zanetto A, Mattioli B, et al. Reduction of the risk of hepatocellular carcinoma over time using direct-acting antivirals: a propensity score analysis of a real-life cohort (PITER HCV). Viruses. 2024;16(5):682. https://doi.org/10.3390/v16050682CrossRefPubMedPubMedCentral

40.

Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J, Elashoff D, Choi G, Durazo FA, El-Kabany MM, Han SB, Saab S. Decrease of alpha-fetoprotein in patients with cirrhosis treated with direct-acting antivirals. J Clin Transl Hepatol. 2017;5(1):43–9. https://doi.org/10.14218/JCTH.2016.00057.PubMedPubMedCentral

41.

Elbadry M, Badawi M, Youssef N, Duracinsky M, Saleh SA, Funk A, Elessawy H, Rumpler E, Sayed K, Vasiliu A, Madec Y. Impact of treating chronic hepatitis C with direct acting antivirals on health-related quality of life: a real-life Egyptian experience. Egypt Liver J. 2024;14(1):14. https://doi.org/10.1186/s43066-024-00317-8CrossRef

42.

Kazankov K, Rode A, Simonsen K, Villadsen GE, Nicoll A, Møller HJ, Lim L, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Vilstrup H, Frystyk J, Grønbæk H. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma. Scand J Clin Lab Invest. 2016;76(1):64–73. https://doi.org/10.3109/00365513.2015.1099722CrossRefPubMed

43.

de Souza-Cruz S, Victória MB, Tarragô AM, da Costa AG, Pimentel JP, Pires EF, Araújo Lde P, Coelho-dos-Reis JG, Gomes Mde S, Amaral LR, Teixeira-Carvalho A, Martins-Filho OA, Victória Fda S, Malheiro A. Liver and blood cytokine microenvironment in HCV patients is associated to liver fibrosis score: a proinflammatory cytokine ensemble orchestrated by TNF and tuned by IL-10. BMC Microbiol. 2016;16:3. https://doi.org/10.1186/s12866-015-0610-6CrossRefPubMedPubMedCentral

44.

Cairoli V, De Matteo E, Casciato P, Ameigeiras B, Preciado MV, Valva P. The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects. PLoS ONE. 2022;17(7):e0270911. https://doi.org/10.1371/journal.pone.0270911CrossRefPubMedPubMedCentral

45.

Beudeker BJB, van der Groothuismink ZMA, Debes JD, Boonstra A. Circulating cytokines reflect the etiology-specific immune environment in cirrhosis and HCC. Cancers (Basel). 2022;14(19):4900. https://doi.org/10.3390/cancers14194900CrossRefPubMed

46.

Minami K, Hiwatashi K, Ueno S, Sakoda M, Iino S, Okumura H, Hashiguchi M, Kawasaki Y, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S. Prognostic significance of CD68, CD163 and folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med. 2018;15(5):4465–76. https://doi.org/10.3892/etm.2018.5959CrossRefPubMedPubMedCentral

47.

Zhang Y, Huang C, Nie Y, Liu Q, Xiao N, Liu L, Zhu X. Soluble CD163 is a predictor of mortality in patients with decompensated cirrhosis. Front Med (Lausanne). 2021;8:698502. https://doi.org/10.3389%2 Ffmed.2021.698502.CrossRefPubMed

48.

Shakiba E, Ramezani M, Sadeghi M. Evaluation of serum interleukin-10 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis. Clin Exp Hepatol. 2018;4(1):35–40. https://doi.org/10.5114/ceh.2018.73484.CrossRefPubMedPubMedCentral

49.

El-Emshaty HM, Nasif WA, Mohamed IE. Serum cytokine of IL-10 and IL-12 in chronic liver disease: the immune and inflammatory response. Dis Markers. 2015;2015(707254). https://doi.org/10.1 155/2015/707254.

50.

Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS, Hwang SG, An S, Yoon G, Gye MC, Yi JM, Kim MJ, Lee SJ. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene. 2017;36(8):1167–8. https://doi.org/10.1038/onc.2016.294CrossRefPubMed

51.

Bhat AA, Syed N, Therachiyil L, Nisar S, Hashem S, Macha MA, Yadav SK, Krishnankutty R, Muralitharan S, Al-Naemi H, Bagga P, Reddy R, Dhawan P, Akobeng A, Uddin S, Frenneaux MP, El-Rifai W, Haris M. Claudin-1, a double-edged Sword in Cancer. Int J Mol Sci. 2020;21(2):569. https://doi.org/10.3390/ijms21020569CrossRefPubMedPubMedCentral

52.

Matsuoka T, Yashiro M. The role of the transforming growth factor-β signaling pathway in gastrointestinal cancers. Biomolecules. 2023;13(10):1551. https://doi.org/10.3390/biom13101551CrossRefPubMedPubMedCentral

53.

Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023;14:1133308. https://doi.org/10.3389/fimmu.2023.1133308CrossRefPubMedPubMedCentral

54.

Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol. 2013;14(10):986–95. https://doi.org/10.1038/ni.2705.CrossRefPubMedPubMedCentral

55.

Feng D, Huang WY, Niu XL, Hao S, Zhang LN, Hu YJ. Significance of macrophage subtypes in the peripheral blood of children with systemic juvenile idiopathic arthritis. Rheumatol Ther. 2021;8(4):1859–70. https://doi.org/10.1007/s40744-021-00385-xCrossRefPubMedPubMedCentral

56.

Chen CJ, Wang HC, Hou YC, Wu YY, Shieh CC, Shan YS. Blocking M2-like macrophage polarization using decoy oligodeoxynucleotide-based gene therapy prevents immune evasion for pancreatic cancer treatment. Mol Cancer Ther. 2024. https://doi.org/10.1158/1535-7163.MCT-23-0767CrossRefPubMedPubMedCentral

57.

Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol. 2014;5:514. https://doi.org/10.3389/fimmu.2014.00514.CrossRefPubMedPubMedCentral

58.

Mandel I, Paperna T, Glass-Marmor L, Volkowich A, Badarny S, Schwartz I, Vardi P, Koren I, Miller A. Tight junction proteins expression and modulation in immune cells and multiple sclerosis. J Cell Mol Med. 2012;16(4):765–75. https://doi.org/10.1111/j.1582-4934.2011.01380.x.CrossRefPubMedPubMedCentral

59.

Arvanitakis K, Koletsa T, Mitroulis I, Germanidis G. Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy. Cancers (Basel). 2022;14(1):226. https://doi.org/10.3390/cancers14010226CrossRefPubMed

60.

Song X, Yao Z, Yang J, Zhang Z, Deng Y, Li M, Ma C, Yang L, Gao X, Li W, Liu J, Wei L. HCV core protein binds to gC1qR to induce A20 expression and inhibit cytokine production through MAPKs and NF-κB signaling pathways. Oncotarget. 2016;7(23):33796–808. https://doi.org/10.18632/oncotarget.9304CrossRefPubMedPubMedCentral

61.

Carlini V, Noonan DM, Abdalalem E, Goletti D, Sansone C, Calabrone L, Albini A. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol. 2023;14:1161067. https://doi.org/10.3389/fimmu.2023.1161067CrossRefPubMedPubMedCentral

Title: Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals
Authors: Reem El-Shenawy
Rehab I. Moustafa
Naiera M. Helmy
Yasmine S. El-Abd
Ashraf A. Tabll
Yasser K. Elesnawy
Heba Shawky
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2024
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-024-02551-3

HSV-1 immune escapes in microglia by down-regulating GM130 to inhibit TLR3-mediated innate immune responses

Open Access
Herpes Simplex Encephalitis
Research

Causal relationships between gut microbiota, plasma metabolites, and HIV infection: insights from Mendelian randomization and mediation analysis

Open Access
Human Immunodeficiency Virus
Research

ZNF148 inhibits HBV replication by downregulating RXRα transcription

Open Access
Hepatitis B
Research

Altered colonic microflora and its metabolic profile in mice with acute viral myocarditis induced by coxsackievirus B3

Open Access
Research

Grapevine Pinot gris virus spreads in infected vineyards: latent infections have no direct impact on grape production

Open Access
Research

Distribution of HPV genotypes in Mashhad, Iran: insights from a 2022–2023 study

Open Access
Human Papillomavirus
Research

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content